To study the spectrum of tremors and compare safety and efficacy of propranolol versus gabapentin in essential tremor.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/09/002991

Enrollment

Registered

2012-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATIENTS WITH TREMORS

Interventions

Intervention1: PROPRANOLOL GABAPENTIN: PROPRANOLOL 40 MG TDS FOR 4 WEEKS GABAPENTIN 600 MG TDS FOR 4 WEEKS Control Intervention1: GABAPENTIN: GABAPENTIN 600 mg TDS FOR 4 WEEKS

Eligibility

Inclusion criteria

Inclusion criteria: 1 DIAGNOSIS OF ESSENTIAL TREMOR 2 AGE OF PATIENT > 18 YEARS 3 INFORMED CONSENT

Exclusion criteria

Exclusion criteria: 1. Chronic obstructive airway disease 2. Diabetes 3. Cardiac and renal disease 4. Severe depression 5. Age of patient 6. Known allergy to drugs under study 7. Secondary causes of tremor like drug induce, hyperthyroidism

Design outcomes

Primary

Measure	Time frame
Primary outcome is tremor reduction more than 50 percent.Timepoint: 10 weeks.	—

Secondary

Measure	Time frame
Secondary outcome is maximum dose achieved or side effect achieved.Timepoint: 10 weeks.	—

Countries

India

Contacts

Public ContactPROF U K MISRA

SGPGIMS

drukmisra@rediffmail.com05222494167

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026